This new collaboration between Vyant Bio, Ordaōs Bio and Cellaria reduces the risk of drug discovery through artificial intelligence and in vitro avatar clinical studies.
Vyant Bio, an advanced biotechnology drug discovery company, Ordaōs Bio, an artificial intelligence (AI) -based drug discovery company, and Cellaria, a biotechnology company specializing in cell modeling, announced on April 22, 2021 that they have entered into a collaboration will attempt to jeopardize the development of therapeutics with small proteins. The partnership plans to introduce a model for rapid iteration of therapeutic design using AI and in vitro Avatar clinical trials. This model enables the design, development and testing of potential therapeutics for specific patient populations during preclinical development with the aim of providing an early detection system for the effectiveness of a drug in different patient cohorts prior to clinical trials.
As part of the collaboration, each company’s unique capabilities will help develop, manufacture and test small protein therapeutics that target multiple biomarkers derived from sequencing the entire genome of patient populations. Ordaōs will use its proprietary AI to generate in-silico protein sequences designed to bind specific disease targets and serve as a blueprint for the collaborative team’s experts in preclinical in vitro and in vivo drug discovery. This blueprint will be used to make the prospective protein therapeutic and quickly iterate the structure using an efficient expression system. Cellaria’s patient-specific cell model cohorts will be used to critically screen the purified protein for target binding and further optimize the protein to improve performance in a range of disease-specific genetic biomarker-expressing cells. Once the protein has been fully optimized by the team, Vyant Bio will aim to provide regulatory readiness and a maximally risk-free drug candidate. The combined solution will deliver human-based data and insights that are normally only available after an expensive clinical trial, the companies said in a press release.
Cellaria uses cell biology in novel ways to gain insight into the performance of a therapeutic in specific patient populations prior to clinical trials. In this collaboration, the company will offer scientists the opportunity to test the performance of a drug in a range of patient cohorts. The in-vitro and three-dimensional Cellaria models of tumor and metastasis niches are directly linked to a patient’s disease state and enable several parametric depth data sets in genomics, proteomics and combinatorial analysis.
Ordaōs meanwhile uses generative AI technology to accelerate the discovery and development process of mini-protein drugs. In this collaboration, Ordaōs offers a pipeline of digitally optimized therapeutics for further development.
“Vyant Bio is committed to transforming the way drugs are discovered by rapidly adapting to exciting new technologies and combining skills to leverage their strengths,” said Jay Roberts, CEO of Vyant Bio, in the press release. “Our collaboration with Ordaōs and Cellaria enables us all to jointly design and develop superior therapeutics and position them to be as successful as possible before they come to the clinic.”
“Working with the Ordaōs and Vyant Bio teams was incredibly important to us. It is very rewarding to see the abundance of patient data and cells that are so seamlessly used to inform and guide the design of a therapeutic, ”added David Deems, President and Founder of Cellaria, in the press release. “We’re developing a repeatable process that uses well-defined patient cohorts to learn as much as possible before starting a clinical trial.”
“We are very excited to be working with Vyant Bio and Cellaria to advance our vision to change the way we deliver therapeutics to patients. At Ordaōs, we believe that designing, not discovering, drugs with AI is now possible and enables us to think bigger as we imagine the impact we can have on people’s lives, “said David Longo, CEO by Ordaōs, in the press release.
“The ultimate goal is to use advanced AI to develop the next generation of highly effective and safe biologics for treating cancer and inflammatory diseases, creating transformative treatment options for potentially millions of patients worldwide. We believe that this new approach will significantly accelerate drug research and development overall and make the new drugs available to patients much faster than the traditional drug development approach. Patients suffering from chronic and life threatening diseases cannot wait. That is why this new collaboration is so important, ”added Ülo Palm, Ordaōs Chief Medical Officer, in the press release.
The three companies will advance their drug design and development strategies through a series of projects targeting cancer, pancreatic and autoimmune diseases. As the project progresses, the therapeutic risk reduction strategy will continue to incorporate human-based biology and analysis software from StemoniX, a wholly-owned subsidiary of Vyant Bio.
Source: the basement